Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
78% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. ALNY: No Debt )
ALNY' s 10-Year Cash to Debt Range
Min: 3.29   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ALNY's Equity to Asset is ranked higher than
89% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALNY: 0.92 )
ALNY' s 10-Year Equity to Asset Range
Min: -0.99   Max: 0.92
Current: 0.92

-0.99
0.92
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
94% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 51.03
M-Score: -3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1040.04
ALNY's Operating margin (%) is ranked higher than
59% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. ALNY: -1040.04 )
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93   Max: -28.95
Current: -1040.04

-14236.93
-28.95
Net-margin (%) -993.24
ALNY's Net-margin (%) is ranked higher than
59% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ALNY: -993.24 )
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3   Max: -27.3
Current: -993.24

-14223.3
-27.3
ROE (%) -55.10
ALNY's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ALNY: -55.10 )
ALNY' s 10-Year ROE (%) Range
Min: -336.03   Max: -13.08
Current: -55.1

-336.03
-13.08
ROA (%) -46.80
ALNY's ROA (%) is ranked higher than
69% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. ALNY: -46.80 )
ALNY' s 10-Year ROA (%) Range
Min: -97.61   Max: -5.01
Current: -46.8

-97.61
-5.01
ROC (Joel Greenblatt) (%) -2289.78
ALNY's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. ALNY: -2289.78 )
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1053.7   Max: -168.68
Current: -2289.78

-1053.7
-168.68
Revenue Growth (3Y)(%) -31.40
ALNY's Revenue Growth (3Y)(%) is ranked higher than
65% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. ALNY: -31.40 )
ALNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 108
Current: -31.4

0
108
EBITDA Growth (3Y)(%) 12.90
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ALNY: 12.90 )
ALNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.8   Max: 36.5
Current: 12.9

-64.8
36.5
EPS Growth (3Y)(%) 11.70
ALNY's EPS Growth (3Y)(%) is ranked higher than
96% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ALNY: 11.70 )
ALNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7   Max: 28.6
Current: 11.7

-66.7
28.6
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ALNY Guru Trades in Q1 2014

George Soros 3,092 sh (New)
Jim Simons 158,700 sh (New)
Steven Cohen 140,522 sh (+209.28%)
Vanguard Health Care Fund 4,524,800 sh (+10.22%)
Columbia Wanger 902,764 sh (-52.73%)
» More
Q2 2014

ALNY Guru Trades in Q2 2014

Vanguard Health Care Fund 4,973,900 sh (+9.93%)
Jim Simons Sold Out
George Soros Sold Out
Columbia Wanger 784,500 sh (-13.1%)
» More
Q3 2014

ALNY Guru Trades in Q3 2014

Steven Cohen 12,100 sh (New)
Vanguard Health Care Fund 5,277,100 sh (+6.1%)
Pioneer Investments 324,287 sh (unchged)
Columbia Wanger 554,000 sh (-29.38%)
» More
Q4 2014

ALNY Guru Trades in Q4 2014

Bill Frels 2,200 sh (New)
Paul Tudor Jones 3,540 sh (New)
John Griffin 430,000 sh (New)
Pioneer Investments 483,213 sh (+49.01%)
Steven Cohen Sold Out
Vanguard Health Care Fund 5,030,100 sh (-4.68%)
Columbia Wanger 477,700 sh (-13.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-12-31 New Buy0.51%$72.85 - $106.59 $ 101.539%430000
George Soros 2014-06-30 Sold Out $48.87 - $70.76 $ 101.5371%0
George Soros 2014-03-31 New Buy$61.07 - $93.28 $ 101.5332%3092
Vanguard Health Care Fund 2013-12-31 Add 611.72%0.7%$50.79 - $66.91 $ 101.5371%4105200
Vanguard Health Care Fund 2013-09-30 New Buy0.13%$35.84 - $64.07 $ 101.53104%576800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: 23.64 )
N/A
P/B 8.70
ALNY's P/B is ranked higher than
69% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ALNY: 8.70 )
ALNY' s 10-Year P/B Range
Min: 1.58   Max: 21.38
Current: 8.7

1.58
21.38
P/S 193.50
ALNY's P/S is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. ALNY: 193.50 )
ALNY' s 10-Year P/S Range
Min: 3.09   Max: 196.96
Current: 193.5

3.09
196.96
EV-to-EBIT -20.08
ALNY's EV-to-EBIT is ranked higher than
57% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: -20.08 )
ALNY' s 10-Year EV-to-EBIT Range
Min: -58.7   Max: 0.6
Current: -20.08

-58.7
0.6
Current Ratio 11.31
ALNY's Current Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ALNY: 11.31 )
ALNY' s 10-Year Current Ratio Range
Min: 1.88   Max: 12.38
Current: 11.31

1.88
12.38
Quick Ratio 11.31
ALNY's Quick Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ALNY: 11.31 )
ALNY' s 10-Year Quick Ratio Range
Min: 1.88   Max: 12.38
Current: 11.31

1.88
12.38
Days Sales Outstanding 3.75
ALNY's Days Sales Outstanding is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. ALNY: 3.75 )
ALNY' s 10-Year Days Sales Outstanding Range
Min: 0.57   Max: 99.74
Current: 3.75

0.57
99.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.16
ALNY's Price/Net Cash is ranked higher than
80% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. ALNY: 14.16 )
ALNY' s 10-Year Price/Net Cash Range
Min: 3.7   Max: 92.77
Current: 14.16

3.7
92.77
Price/Net Current Asset Value 14.14
ALNY's Price/Net Current Asset Value is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. ALNY: 14.14 )
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.61   Max: 91.44
Current: 14.14

3.61
91.44
Price/Tangible Book 8.60
ALNY's Price/Tangible Book is ranked higher than
74% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. ALNY: 8.60 )
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 15.17
Current: 8.6

2.64
15.17
Price/Median PS Value 9.39
ALNY's Price/Median PS Value is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. ALNY: 9.39 )
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 7.22
Current: 9.39

0.16
7.22
Earnings Yield (Greenblatt) -4.90
ALNY's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ALNY: -4.90 )
ALNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6   Max: 1781.6
Current: -4.9

-6
1781.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc is a Delaware corporation that was formed in May 2003. The Company is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. The Companys core product Alnylam 5x15, was launched in January 2011 and is focused on the development and commercialization of novel RNAi therapeutics as genetic medicines. Its genetic medicine programs are RNAi therapeutics directed towards genetically defined targets for the treatment of diseases with high unmet medical need. The Company is currently advancing the following core programs in clinical or pre-clinical development: patisiran (the International Nonproprietary Name for ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, in patients with familial amyloidotic polyneuropathy, or FAP; ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR in development for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy, or FAC, and senile systemic amyloidosis, or SSA; ALN-AT3, an RNAi therapeutic targeting antithrombin, or AT, in development for the treatment of hemophilia and rare bleeding disorders, or RBD; ALN-CC5, an RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1, or ALAS-1, in development for the treatment of hepatic porphyrias, including acute intermittent porphyria, or AIP; ALN-PCSsc, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, in development for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin, or AAT, in development for the treatment of AAT deficiency liver disease; ALN-TMP, an RNAi therapeutic targeting transmembrane protease, serine 6, or TMPRSS6, in development for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angioprotein-like 3, or ANGPTL3, in development for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other yet to be disclosed programs. The Companys product platform provides a capability for an approach to identifying RNAi therapeutic product candidates through sequence selection, potency selection, stabilization by chemical modification, improvement of biodistribution and cellular uptake by various chemical conjugates and formulations. Its competitors include Novartis, Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira, Sylentis and Dicerna Pharmaceuticals, Inc., Regulus, Rosetta Genomics, Santaris Pharma A/S, or
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
comment on ALNY Mar 09 2013 
comment on ALNY Mar 02 2013 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 06 2009 
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results Feb 17 2009 


More From Other Websites
QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Mar 02 2015
Endo (ENDP) Beats Q4 Earnings, Announces Divestments - Analyst Blog Mar 02 2015
Aegerion's Q4 Loss Narrows Y/Y, Ups Juxtapid Sales View - Analyst Blog Feb 27 2015
Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference Feb 25 2015
Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference Feb 25 2015
ALNYLAM PHARMACEUTICALS, INC. Financials Feb 20 2015
Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Feb 19 2015
Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog Feb 19 2015
Alnylam to Webcast Presentation at 2015 RBC Capital Markets' Global Healthcare Conference Feb 18 2015
Alnylam to Webcast Presentation at 2015 RBC Capital Markets’ Global Healthcare Conference Feb 18 2015
Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog Feb 18 2015
Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Feb 17 2015
Company News for February 17, 2015 - Corporate Summary Feb 17 2015
Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog Feb 17 2015
Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog Feb 16 2015
10-K for Alnylam Pharmaceuticals, Inc. Feb 15 2015
Zacks Rank #1 Additions for Friday - Tale of the Tape Feb 13 2015
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog Feb 13 2015
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog Feb 13 2015
Alnylam reports 4Q loss Feb 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK